Dual Targeting of WEE1 and PLK1 by AZD1775 Elicits Single Agent Cellular Anticancer Activity
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Inhibition of the WEE1 tyrosine kinase enhances anticancer chemotherapy efficacy. Accordingly, the WEE1 inhibitor AZD1775 (previously MK-1775) is currently under evaluation in clinical trials for cancer in combination with chemotherapy. AZD1775 has been reported to display high selectivity and is therefore used in many studies as a probe to interrogate WEE1 biology. However, AZD1775 also exhibits anticancer activity as a single agent although the underlying mechanism is not fully understood. Using a chemical proteomics approach, we here describe a proteome-wide survey of AZD1775 targets in lung cancer cells and identify several previously unknown targets in addition to WEE1. In particular, we observed polo-like kinase 1 (PLK1) as a new target of AZD1775. Importantly, in vitro kinase assays showed PLK1 and WEE1 to be inhibited by AZD1775 with similar potency. Subsequent loss-of-function experiments using RNAi for WEE1 and PLK1 suggested that targeting PLK1 enhances the pro-apoptotic and antiproliferative effects observed with WEE1 knockdown. Combination of RNAi with AZD1775 treatment suggested WEE1 and PLK1 to be the most relevant targets for mediating AZD1775's anticancer effects. Furthermore, disruption of WEE1 by CRISPR-Cas9 sensitized H322 lung cancer cells to AZD1775 to a similar extent as the potent PLK1 inhibitor BI-2536 suggesting a complex crosstalk between PLK1 and WEE1. In summary, we show that AZD1775 is a potent dual WEE1 and PLK1 inhibitor, which limits its use as a specific molecular probe for WEE1. However, PLK1 inhibition makes important contributions to the single agent mechanism of action of AZD1775 and enhances its anticancer effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A dual inhibitor targeting both WEE1 and PLK1 has been developed and may be useful for overcoming resistance to KRAS inhibition [145].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [145]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive analysis of kinase inhibitor selectivity
Davis, M. I., Hunt, J. P., Herrgard, S., Ciceri, P., Wodicka, L. M., Pallares, G., Hocker, M., Treiber, D. K., & Zarrinkar, P. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1990 · Cited by 2,409
COSMIC: exploring the world's knowledge of somatic mutations in human cancer
Forbes, S. A., Beare, D., Gunasekaran, P., Leung, K., Bindal, N., Boutselakis, H., Ding, M., Bamford, S., Cole, C., Ward, S., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1075 · Cited by 2,283
ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
Bergethon, K., Shaw, A. T., Ignatius Ou, S.-H., Katayama, R., Lovly, C. M., McDonald, N. T., Massion, P. P., Siwak-Tapp, C., Gonzalez, A., Fang, R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.6345 · Cited by 1,555
Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors
Bantscheff, M., Eberhard, D., Abraham, Y., Bastuck, S., Boesche, M., Hobson, S., Mathieson, T., Perrin, J., Raida, M., Rau, C., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1328 · Cited by 1,034
Inactivation of the p34 cdc2 -Cyclin B Complex by the Human WEE1 Tyrosine Kinase
Parker, L. L., & Piwnica-Worms, H. (1992) · Science · doi:10.1126/science.1384126 · Cited by 716
mik1 and wee1 cooperate in the inhibitory tyrosine phosphorylation of cdc2
Lundgren, K., Walworth, N., Booher, R., Dembski, M., Kirschner, M., & Beach, D. (1991) · Cell · doi:10.1016/0092-8674(91)90266-2 · Cited by 683
SAINTexpress: Improvements and additional features in Significance Analysis of INTeractome software
Teo, G., Liu, G., Zhang, J., Nesvizhskii, A. I., Gingras, A.-C., & Choi, H. (2014) · Journal of Proteomics · doi:10.1016/j.jprot.2013.10.023 · Cited by 682
Targeting the cancer kinome through polypharmacology
Knight, Z. A., Lin, H., & Shokat, K. M. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2787 · Cited by 674
Rix, U., Hantschel, O., Dürnberger, G., Remsing Rix, L. L., Planyavsky, M., Fernbach, N. V., Kaupe, I., Bennett, K. L., Valent, P., Colinge, J., et al. (2007) · Blood · doi:10.1182/blood-2007-07-102061 · Cited by 671
Self-citationMultifaceted polo-like kinases: drug targets and antitargets for cancer therapy
Strebhardt, K. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3184 · Cited by 653
Research works printed but not linked: 1
- 10.1158/1535-7163.MCT-15-0692-T · doi:10.1158/1535-7163.mct-15-0692-t
Cited by
Emran, T. B., Shahriar, A., Mahmud, A. R., Rahman, T., Abir, M. H., Siddiquee, M. F. R., Ahmed, H., Rahman, N., Nainu, F., Wahyudin, E., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.891652 · Cited by 606
Targeted protein degradation: A promise for undruggable proteins
Samarasinghe, K. T. G., & Crews, C. M. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2021.04.011 · Cited by 271
A new wave of innovations within the DNA damage response
Li, Q., Qian, W., Zhang, Y., Hu, L., Chen, S., & Xia, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01548-8 · Cited by 188
“Of note, an unbiased mass spectrometry (MS)-based chemical proteomics survey uncovered a set of kinases hit by adavosertib, and adavosertib was equally potent against WEE1 and PLK1.(190) Severe AEs especially gastrointestinal toxicities and myelosuppression were observed in patients receiving adavosertib.”
BackgroundInfluentialTargeting DNA repair pathway in cancer: Mechanisms and clinical application
Wang, M., Chen, S., & Ao, D. (2021) · MedComm · doi:10.1002/mco2.103 · Cited by 150
Structural Basis of Wee Kinases Functionality and Inactivation by Diverse Small Molecule Inhibitors
Zhu, J., Cuellar, R. A. D., Berndt, N., Lee, H. E., Olesen, S. H., Martin, M. P., Jensen, J. T., Georg, G. I., & Schönbrunn, E. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00996 · Cited by 113
“cancer cells.(33) Molecular modeling using the well-known structure of the PLK1 kinase domain”
Self-citationDevelopment and Characterization of a Wee1 Kinase Degrader
Li, Z., Pinch, B. J., Olson, C. M., Donovan, K. A., Nowak, R. P., Mills, C. E., Scott, D. A., Doctor, Z. M., Eleuteri, N. A., Chung, M., et al. (2020) · Cell Chemical Biology · doi:10.1016/j.chembiol.2019.10.013 · Cited by 103
“Furthermore, AZD1775 has off-target activity against other kinases; for example, it is equipotent against recombinant Wee1 and the Ser/Thr kinase, PLK1(Wright et al., 2017), and analogs of AZD1775 have been reported that maintain potency against Wee1 but with reduced single-agent cellular cytotoxicity(Matheson et al.”
BackgroundInfluentialPolo-like Kinase 1 Inhibitors in Human Cancer Therapy: Development and Therapeutic Potential
Zhang, J., Zhang, L., Wang, J., Ouyang, L., & Wang, Y. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00614 · Cited by 100
WEE1 kinase limits CDK activities to safeguard DNA replication and mitotic entry
Elbæk, C. R., Petrosius, V., & Sørensen, C. S. (2020) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2020.111694 · Cited by 94
Xu, H., George, E. M., Kinose, Y., Kim, H., Shah, J., Peake, J. D., Ferman, B. I., Medvedev, S., Murtha, T., Barger, C. J., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100394 · Cited by 102
“However, monotherapy is less effective or requires high doses (WEE1i > 200 nM) that are toxic to normal cells and associated with potential off-target effects (Figure 1).(50) Treatment with WEE1i alone also significantly increased ATR-CHK1 signaling (pCHK1) but the addition of ATRi to WEE1i blocked WEE1i-mediated indu…”
BackgroundDouble‐strand DNA break repair: molecular mechanisms and therapeutic targets
Tan, J., Sun, X., Zhao, H., Guan, H., Gao, S., & Zhou, P. (2023) · MedComm · doi:10.1002/mco2.388 · Cited by 122
New Horizons of Synthetic Lethality in Cancer: Current Development and Future Perspectives
Previtali, V., Bagnolini, G., Ciamarone, A., Ferrandi, G., Rinaldi, F., Myers, S. H., Roberti, M., & Cavalli, A. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00113 · Cited by 87
Lee, J. W., Parameswaran, J., Sandoval-Schaefer, T., Eoh, K. J., Yang, D., Zhu, F., Mehra, R., Sharma, R., Gaffney, S. G., Perry, E. B., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0440 · Cited by 79
“In parallel, AURKA activates the PLK1 kinase via direct phosphorylation (17); PLK1, in turn, also phosphorylates and activates the CDC25 phosphatases (18), and importantly, phosphorylates and inhibits WEE1, the kinase responsible for introducing the inhibitory CDK1 phosphorylation (19).”
BackgroundInfluentialTargeting Wee1 kinase as a therapeutic approach in Hematological Malignancies
Vakili‐Samiani, S., Jalil, A. T., Abdelbasset, W. K., Yumashev, A. V., Karpisheh, V., Jalali, P., Adibfar, S., Ahmadi, M., Feizi, A. A. H., & Jadidi‐Niaragh, F. (2021) · DNA repair · doi:10.1016/j.dnarep.2021.103203 · Cited by 76
Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapy
Fu, S., Wang, Y., Keyomarsi, K., & Meric-Bernstein, F. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1511700 · Cited by 80
“9 (Wee2), and 3 nM (PLK1) using a quantitative real-time polymerase chain reaction (qPCR) method that detects the associated DNA label tagged to the kinase [46].”
MethodUpregulation of Myt1 Promotes Acquired Resistance of Cancer Cells to Wee1 Inhibition
Lewis, C. W., Bukhari, A. B., Xiao, E. J., Choi, W.-S., Smith, J. D., Homola, E. M., Mackey, J. R., Campbell, S. D., Gamper, A. M., & Chan, G. K. T. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-1961 · Cited by 74
Lin, X., Chen, D., Zhang, C., Zhang, X., Li, Z., Dong, B., Gao, J., & Shen, L. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0790-7 · Cited by 62
Patel, P., Sun, L., Robbins, Y. L., Clavijo, P. E., Friedman, J., Silvin, C. J., Waes, C. V., Cook, J. A., Mitchell, J. B., & Allen, C. T. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1638207 · Cited by 48
Dabrafenib inhibits the growth of BRAF‐WT cancers through CDK16 and NEK9 inhibition
Phadke, M. A., Rix, L. L. R., Smalley, I., Bryant, A. T., Luo, Y., Lawrence, H. R., Schaible, B., Chen, Y. A., Rix, U., & Smalley, K. S. M. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12152 · Cited by 49
“SDS/PAGE, in-gel digestion with trypsin, and LC-MS/MS analyses were performed as described previously (Wright et al., 2017).”
BackgroundMethodSelf-citationRoidos, P., Sungalee, S., Benfatto, S., Serçin, Ö., Stütz, A. M., Abdollahi, A., Mauer, J., Zenke, F. T., Korbel, J. O., & Mardin, B. R. (2020) · Nature Communications · doi:10.1038/s41467-020-17962-3 · Cited by 45
“For this reason, understanding the pro fi les of these inhibitors may have important implications for the correct evaluation of their biological effects in DNA repair choice, and their effects in the cells 56 – 60 .”
Adavosertib and beyond: Biomarkers, drug combination and toxicity of WEE1 inhibitors
Zhang, C., Peng, K., Liu, Q., Huang, Q., & Liu, T. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104233 · Cited by 45
CRISPR/Cas9 for overcoming drug resistance in solid tumors
Saber, A., Liu, B., Ebrahimi, P., & Haisma, H. J. (2019) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-019-00240-z · Cited by 47
“They showed that CRISPR-mediated knockout ofWEE1 sensitized lung cancer cells (H322) to AZD1775 to a similar level as BI-2536, a potent PLK1 inhibitor [62].”
BackgroundStructure-activity relationships of Wee1 inhibitors: A review
Du, X., Li, J., Luo, X., Li, R., Li, F., Zhang, Y., Shi, J., & He, J. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112524 · Cited by 42
Palve, V. C., Knezevic, C. E., Bejan, D. S., Luo, Y., Li, X., Novakova, S., Welsh, E. A., Fang, B., Kinose, F., Haura, E. B., et al. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.07.008 · Cited by 41
Self-citationMolecular and enzoinformatics perspectives of targeting Polo-like kinase 1 in cancer therapy
Shakil, S., Baig, M. H., Tabrez, S. S. M., Rizvi, S. M. D., Zaidi, S. K., Ashraf, G. M., Ansari, S. A., Khan, A. A. P., Al-Qahtani, M. H., Abuzenadah, A. M., et al. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.11.004 · Cited by 36
Synthetic and Medicinal Chemistry Approaches Toward WEE1 Kinase Inhibitors and Its Degraders
Alli, V. J., Yadav, P., Suresh, V., & Jadav, S. S. (2023) · ACS Omega · doi:10.1021/acsomega.3c01558 · Cited by 36
Selective Wee1 degradation by PROTAC degraders recruiting VHL and CRBN E3 ubiquitin ligases
Aublette, M. C., Harrison, T. A., Thorpe, E. J., & Gadd, M. S. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.128636 · Cited by 35
Selective Wee1 Inhibitors Led to Antitumor Activity In Vitro and Correlated with Myelosuppression
Guler, S. Y., DiPoto, M. C., Crespo, A., Caldwell, R. D., Doerfel, B., Grossmann, N., Ho, K., Huck, B. R., Jones, C. C., Lan, R., et al. (2023) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.2c00481 · Cited by 37
Tian, L., Yao, K., Liu, K., Han, B., Dong, H., Zhao, W., Jiang, W., Qiu, F., Qu, L., Wu, Z., et al. (2020) · Oncogene · doi:10.1038/s41388-020-1205-8 · Cited by 33
“PLK1-mediated mitotic events such as microtubule rearrangement have also been found to reduce the efficacy of chemotherapeutic agents [14].”
BackgroundChen, D., Lin, X., Gao, J., Shen, L., Li, Z., Dong, B., Zhang, C., & Zhang, X. (2018) · BioMed Research International · doi:10.1155/2018/5813292 · Cited by 34
“Predictive value of alternative newfound targets of AZD1775, such as PLK1 [44], is also worthy of an investigation.”
BackgroundKoh, S. (2022) · Cellular Signalling · doi:10.1016/j.cellsig.2022.110310 · Cited by 36
Wee1 Rather Than Plk1 Is Inhibited by AZD1775 at Therapeutically Relevant Concentrations
Serpico, A. F., D’Alterio, G., Vetrei, C., Monica, R. D., Nardella, L., Visconti, R., & Grieco, D. (2019) · Cancers · doi:10.3390/cancers11060819 · Cited by 28
“both in the clinical and in the experimental setting, might be due to the inhibition of both Wee1 and Plk1 [12,19].”
BackgroundInfluentialSmall molecule agents for triple negative breast cancer: Current status and future prospects
Ou, Y., Wang, M., Xu, Q., Sun, B., & Jia, Y. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.101893 · Cited by 31
“Adavosertib (AZD1775) Adavosertib is a highly selective small molecule Wee1 and Wee2 kinase inhibitor [120] that can enhance the activity of chemotherapeutic agents that act on DNA structure and function [121].”
BackgroundPitts, T. M., Simmons, D. M., Bagby, S. M., Hartman, S. J., Yacob, B. W., Gittleman, B., Tentler, J. J., Cittelly, D. M., Ormond, D. R., Messersmith, W. A., et al. (2020) · Cancers · doi:10.3390/cancers12030719 · Cited by 28
“9 nM, respectively) [4] that potentiates the activity of many DNA-damaging chemotherapeutics and is currently in clinical development for multiple indications [5].”
BackgroundMatheson, C. J., Casalvieri, K. A., Backos, D. S., & Reigan, P. (2018) · ChemMedChem · doi:10.1002/cmdc.201800188 · Cited by 24
Inhibition of ATR Increases the Sensitivity to WEE1 Inhibitor in Biliary Tract Cancer
Nam, A., Jin, M., Bang, J., Oh, K.-S., Seo, H.-R., Oh, D., & Bang, Y. (2020) · Cancer Research and Treatment · doi:10.4143/crt.2020.080 · Cited by 24
Efficacy of adavosertib therapy against anaplastic thyroid cancer
Lu, Y., Huang, Y., Wu, M., Chou, T., Wong, R. J., & Lin, S. (2021) · Endocrine Related Cancer · doi:10.1530/erc-21-0001 · Cited by 19
Temporal phosphoproteomics reveals WEE1-dependent control of 53BP1 pathway
Petrosius, V., Benada, J., Nielsen, O., Schoof, E. M., & Sørensen, C. S. (2022) · iScience · doi:10.1016/j.isci.2022.105806 · Cited by 21
“In accordance with previous studies, we use a relatively high concentration of adavosertib, reminiscent of the blood serum concentration in clinical studies.(8,15,23,27,28,34) Albeit such concentrations have been they routinely used, they increase the risk of convoluting the data with off-target effects.”
BackgroundMethodXin, M., Wei, J.-H., Yang, C., Liang, G.-B., Su, D., Ma, X., & Zhang, Y. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127051 · Cited by 15
Design, synthesis, and biological evaluation of Wee1 kinase degraders
Zhu, S., Liu, J., Xiao, D., Wang, P., Ma, J., Hu, X., Fu, J., Zhou, Y., Li, J. X., & Lu, W. P. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114786 · Cited by 15
Zhao, X., Chen, Y., Su, H., & Zhang, L. (2023) · Interdisciplinary medicine · doi:10.1002/inmd.20230004 · Cited by 15
Myt1 overexpression mediates resistance to cell cycle and DNA damage checkpoint kinase inhibitors
Sokhi, S., Lewis, C. W., Bukhari, A. B., Hadfield, J., Xiao, E. J., Fung, J., Yoon, Y. J., Hsu, W., Gamper, A. M., & Chan, G. K. T. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1270542 · Cited by 16
Gonzalez-Salinas, F., Martínez-Amador, C., & Treviño, V. (2022) · Gene · doi:10.1016/j.gene.2022.146595 · Cited by 12
Nojima, H., Homma, H., Onozato, Y., Kaida, A., Harada, H., & Miura, M. (2019) · Experimental Cell Research · doi:10.1016/j.yexcr.2019.111720 · Cited by 13
Cyclin E1 overexpression sensitizes ovarian cancer cells to WEE1 and PLK1 inhibition
Xi, Q., Kunita, A., Ogawa, M., Ka, M., Tanimoto, S., Tsuchimochi, S., Nagai, S., Matsunaga, A., Fukuda, T., Watanabe, K., et al. (2025) · Oncogene · doi:10.1038/s41388-025-03312-4 · Cited by 15
“Although adavosertib has been suggested to also target PLK1 [46], it is questionable whether PLK1 inhibition occurs at clinically relevant concentrations, and its classi fi cation as a WEE1/PLK1 dual inhibitor is not as well-established [47].”
Advances in the application of proteomics in lung cancer
Bai, L., Zhang, Z., Xiang, Z., Cai, Y., Zhang, X., & Wu, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.993781 · Cited by 11
“Attention should be paid to its limitations as a highly selective WEE1 probe molecule when developing clinical anticancer application of AZD1775 (69).”
BackgroundInfluentialWarren, N. J. H., Donahue, K. L., & Eastman, A. R. (2019) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00001 · Cited by 10
Toni, T., Viswanathan, R., Robbins, Y. L., Gunti, S., Yang, X., Huynh, A. P., Cheng, H. W., Sowers, A. L., Mitchell, J. B., Allen, C. T., et al. (2023) · Cancers · doi:10.3390/cancers15041029 · Cited by 12
“Although AZD1775 is a well characterised WEE1 inhibitor, it has also been shown to inhibit WEE1 homologs and other G2/M kinases [36].”
BackgroundChilamakuri, R., Rouse, D. C., & Agarwal, S. (2022) · Pharmaceuticals · doi:10.3390/ph15050523 · Cited by 9
Efficacy and Biomarker Analysis of Adavosertib in Differentiated Thyroid Cancer
Lu, Y., Wu, M., Lee, Y.-Y., Chou, T., Wong, R. J., & Lin, S. (2021) · Cancers · doi:10.3390/cancers13143487 · Cited by 9
“Adavosertib is a potent PLK1 inhibitor, with IC50 at nanomolar concentrations (22–34 nmol/L) [40].”
BackgroundATP-binding cassette transporters limit the brain penetration of Wee1 inhibitors
de Gooijer, M. C., Buil, L. C. M., Beijnen, J. H., & van Tellingen, O. (2017) · Investigational New Drugs · doi:10.1007/s10637-017-0539-8 · Cited by 9
“AZD1775 on the other hand was developed as a more specific Wee1 inhibitor, although recent reports suggest that AZD1775 also targets PLK1 [31, 32].”
BackgroundFanale, D., Corsini, L. R., Pedone, E., Randazzo, U., Fiorino, A., Piazza, M. D., Brando, C., Magrin, L., Contino, S., Piraino, P., et al. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104086 · Cited by 15
“Other studies focused on other strategies, such as the simultaneous targeting of WEE1 and PLK1 by AZD1775 to investigate the efficacy of olaparib administration, reporting interesting evidences in GI cancer cell lines (Wright et al., 2017).”
Yang, X., Smith, J. L., Beck, M., Wilkinson, J., Michaud, A., Vasta, J. D., Robers, M. B., & Willson, T. M. (2023) · Molecules · doi:10.3390/molecules28072950 · Cited by 11
“thality target of the DNA damage response [13].”
BackgroundMethodPreparation for mitosis requires gradual CDK1 activation
Akopyan, K., Hao, Z., & Lindqvist, A. (2025) · iScience · doi:10.1016/j.isci.2025.112292 · Cited by 7
“38 ,39 Here, we find that the magnitude of a mitotic delay depends on the time point in G2 phase when Wee1 inhibitors are added.”
Knight, J. L., Clark, A. J., Wang, J., Placzek, A., Bos, P. H., Bhat, S., Bell, J. A., Silvergleid, S., Yin, W., Gray, F., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62722-w · Cited by 11
“Off-target Inhibition of PLK1 24,25 has been hypothesized to contribute to the observed AZD1775 toxicities.”
Syphers, J. L., Wright, J. A., Liu, S., Gee, Y. S., Gao, F., Mudududdla, R., Che, D. Q., Chang, A., Sloan, E. K., Narasimhan, V., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02541 · Cited by 10
CDK2-Mediated Upregulation of TNFα as a Mechanism of Selective Cytotoxicity in Acute Leukemia
Ding, H., Vincelette, N. D., McGehee, C. D., Kohorst, M. A., Koh, B. D., Venkatachalam, A., Meng, X. W., Schneider, P. A., Flatten, K. S., Peterson, K. L., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-1504 · Cited by 7
Differential Response and Resistance to KRAS-Targeted Therapy
Liu, Z., Lenz, H., Yu, J., & Zhang, L. (2025) · Molecular Carcinogenesis · doi:10.1002/mc.23908 · Cited by 7
“A dual inhibitor targeting both WEE1 and PLK1 has been developed and may be useful for overcoming resistance to KRAS inhibition [148].”
Kim, Y. J., Jung, M. E., Lee, J. Y., Lee, Y., Choi, G., & Jeon, M. (2023) · Bulletin of the Korean Chemical Society · doi:10.1002/bkcs.12791 · Cited by 7
Applications of CRISPR/Cas technology against drug-resistant lung cancers: an update
Chaudhary, M., Sharma, P., & Mukherjee, T. K. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-07766-7 · Cited by 4
“Additionally, AZD1755 showed an anticancer effect to a similar extent as shown by PKL1 inhibitor (BI2536) even after CRISPR-mediated disruption of WEE1 in H322 lung cancer cells.”
BackgroundInfluentialCheng, Z., Hwang, S. S., Bhave, M. R., Rahman, T., & Wezen, X. C. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c01252 · Cited by 4
Yang, X., Smith, J. L., Beck, M., Wilkinson, J., Michaud, A., Vasta, J. D., Robers, M. B., & Willson, T. M. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.02.25.529946 · Cited by 4
Syphers, J. L., Wright, J. A., de Nys, R., Silva, T. N., Vrbanac, L., Barratt, K. R., Leeflang, J., Hasan, S. T., Thomson, S. F., Kumar, A., et al. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118838 · Cited by 1
Papadopoulos, K. P., Sharma, M. R., Dummer, R., Colombo, I., Ramelyte, E., Seamon, L. G., Rasco, D. W., Rodríguez-Freixinós, V., Dozio, V., Tat, T., et al. (2026) · European Journal of Cancer · doi:10.1016/j.ejca.2026.116792 · Cited by 1
A Possibility of Synthetic Lethality: Wee1 Kinase as a Promising Treating Target for Cancer
Xue, X., Chen, X. Q., Jiang, Y., Wang, X., Xu, Z., Bei, C., Shi, G., Zhu, Y., Wei, Y., Chen, Y. C., et al. (2026) · Medicinal Research Reviews · doi:10.1002/med.70057 · Cited by 1
“Debio‐0123, a brain‐ penetrant Wee1/Myt1 inhibitor, is under evaluation in multiple phase I/II trials, including monotherapy and combination regimens with temozolomide, carboplatin, and radiotherapy in solid tumors and GBM (e.g., NCT05765812, NCT05109975 and NCT03968653) [180].”
Grassetti, A. V., Hards, R., & Gerber, S. A. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.09.27.461942
“We observed elevated levels of AurkA, AurkB and Plk1 substrate phosphorylation in the G2 but not mitotic datasets (Figures 2D, 2E).”
BackgroundInfluentialDing, H., Vincelette, N. D., McGehee, C. D., Kohorst, M. A., Koh, B. D., Venkatachalam, A., Meng, X. W., Schneider, P. A., Flatten, K. S., Peterson, K. L., et al. (2023) · doi:10.1158/0008-5472.c.6512716.v1
Akopyan, K., & Lindqvist, A. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.15.585186
“The inhibitor AZD1775 has been suggested to also target Plk1, although whether Plk1 inhibition occurs at clinically relevant concentrations has been questioned (Serpico et al., 2019; Wright et al., 2017).”
BackgroundXu, B., Li, H., Yang, C., Su, R., Gao, X., Wang, M., & Gao, X. (2025) · Research Square · doi:10.21203/rs.3.rs-6121020/v1
Current progress in targeting mitotic kinases in PDAC
Barlow, T. M. A., Rooman, I., & Ballet, S. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00162e
Wee1-targeting inhibitors: From virtual screening to lead discovery
Nelen, J., Sarkar, B., Jiménez‐Bernad, J., Darragh, A. C., Hanna, A. M., Servant, N. B., Jahic, M., Villalgordo-Soto, J. M., Georg, G. I., & Pérez‐Sánchez, H. (2026) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2026.118645
Targeting the cell cycle : A novel therapeutic strategy against ATIP3- deficient breast cancer
Haykal, M. M. (2023) · theses.fr (ABES) · doi:10.70675/03dee32bz395cz469ez9a0dzf4c5f2e84330
Recent Progress in Targeting Kinases Involved in the DNA Damage Response for the Treatment of Cancer
Buckley-Benbow, L., Rout, A. M., Fielding, A. B., Parsons, J. L., Gadd, M. S., & Allinson, S. L. (2026) · Targets · doi:10.3390/targets4030024
“It has been proposed that one key issue with adavosertib is its lack of selectivity, as it is also a potent inhibitor of the mitotic regulator polo-like kinase 1 (PLK1) [156].”
Muthuraj, R., Pacharla, M., Kumar, N. A., Gopal, D., Agrawal, M., Sathiyanathan, A. P., Kumar, P., Edwin, R., & Chandrasekaran, J. (2026) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-026-00917-z
“Ada-vosertib (MK-1775) has been shown to exhibit dual WEE1/ PLK1 inhibitory activity, which parallels the dose-limiting haematological toxicity reported in clinical studies [ 18].”
Syphers, J. L., Wright, J. A., Kumar, A., To, N., Elson, L., Krämer, A., Müller, S., Morasch, V., Chang, A., Young, S., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00018
BindingDB Entry 50019498: Design, synthesis, and biological evaluation of Wee1 kinase degraders.
BindingDB (2024) · UC San Diego · doi:10.7270/q2zw1r9s
BindingDB Entry 50019058: Selective Wee1 Inhibitors Led to Antitumor Activity
BindingDB (2024) · UC San Diego · doi:10.7270/q2z89hn6
BindingDB Entry 50018339: Structure-activity relationships of Wee1 inhibitors: A review.
BindingDB (2024) · UC San Diego · doi:10.7270/q2z323w0
Metadata
- Authors
- Wright, G., Golubeva, V., Remsing Rix, L. L., Berndt, N., Luo, Y., Ward, G. A., Gray, J. E., Schonbrunn, E., Lawrence, H. R., Monteiro, A. N. A., & Rix, U.
- Affiliations
- Moffitt Cancer Center (US)
- Drug Discovery Department, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida 33612, United States
- University of South Florida (US)
- Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida 33612, United States
- Corresponding author
- Rix, Uwe
- ORCID
- Venue
- ACS Chemical Biology
- Publisher
- American Chemical Society (ACS)
- Published
- 2017-06-07
- Volume
- 12
- Issue
- 7
- Pages
- 1883-1892
- ISSN
- 1554-8929 (ISSN-L)
- 1554-8937
- PMC
- PMC5551971
- OpenAlex
- W2619325549
- Cited by
- 77
- References
- 44
- Citations by year
- 2026: 8 · 2025: 8 · 2024: 4 · 2023: 15 · 2022: 10 · 2021: 9 · 2020: 7 · 2019: 8 · 2018: 4 · 2017: 4
- FWCI
- 3.50
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- ACS Chemical Biology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01 CA181746)
- H. Lee Moffitt Cancer Center and Research Institute
- Moffitt Cancer Center
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Microtubule and mitosis dynamics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Keywords
- AZD1775, WEE1, PLK1, dual kinase inhibition, lung cancer, chemoproteomics, CRISPR/Cas9, BI2536, apoptosis, antiproliferative activity
- MeSH terms
- Polo-Like Kinase 1, Antineoplastic Agents, Cell Survival, Dose-Response Relationship, Drug, Enzyme Activation, Humans, Lung Neoplasms, Nuclear Proteins, Protein-Tyrosine Kinases, Proto-Oncogene Proteins, Pyrazoles, Pyrimidines, Pyrimidinones, Immunoblotting, Molecular Structure, Drug Delivery Systems, Apoptosis, Protein Serine-Threonine Kinases, Cell Cycle Proteins, Cell Line, Tumor, Cell Proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.